1h Free Analyst Time
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.Speak directly to the analyst to clarify any post sales queries you may have.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 24 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Rheumatoid Arthritis, Inflammation, Atopic Dermatitis (Atopic Eczema), Myelodysplastic Syndrome, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Psoriasis, Chronic Myelomonocytic Leukemia (CMML), Follicular Lymphoma, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Lymphoma, Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous Lupus Erythematosus, Diabetic Nephropathy, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gouty Arthritis (Gout), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Rosacea, Solid Tumor, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) and Unspecified.
The latest report Interleukin 1 Receptor Associated Kinase 4 - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
- Asahi Kasei Pharma Corp
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Bayer AG
- Beijing Hanmi Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Emmaus Life Sciences Inc
- Evommune Inc
- Fresh Tracks Therapeutics Inc
- Gilead Sciences Inc
- Kurome Therapeutics Inc
- Kymera Therapeutics Inc
- Nyrada Inc
- Pfizer Inc
- Rigel Pharmaceuticals Inc
- TG Therapeutics Inc
- Xi'An Yufan Biotechnology Co Ltd
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
- AK-179 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AS-2444697 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZD-6793 - Drug Profile
- Product Description
- Mechanism Of Action
- BAY-1830839 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-986126 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- emavusertib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EVO-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FRTX-02 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GS-5718 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IRAK4 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KM-10544 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KT-413 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KT-474 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- R-289 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- R-835 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit IRAK4 for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules 1 to Inhibit IRAK4 for Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit IRAK1 and IRAK4 for Acute Myelocytic Leukemia and Myelodysplastic Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TQH-3821 - Drug Profile
- Product Description
- Mechanism Of Action
- zabedosertib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- zimlovisertib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ZYF-0116 - Drug Profile
- Product Description
- Mechanism Of Action
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Discontinued Products
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Companies, 2022 (Contd..3)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asahi Kasei Pharma Corp
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Bayer AG
- Beijing Hanmi Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Emmaus Life Sciences Inc
- Evommune Inc
- Fresh Tracks Therapeutics Inc
- Gilead Sciences Inc
- Kurome Therapeutics Inc
- Kymera Therapeutics Inc
- Nyrada Inc
- Pfizer Inc
- Rigel Pharmaceuticals Inc
- TG Therapeutics Inc
- Xi'An Yufan Biotechnology Co Ltd
